Manages severe and persistent pain. ANDA 205629, held by Osmotica Pharm US. Hydromorphone Hydrochloride.
As of Nov 16, 2026, ANDA 205629 (Hydromorphone Hydrochloride), held by Osmotica Pharm US, was first approved by FDA on Jul 7, 2016, with 13 approved supplements and 0 published complete response letters.
Hydromorphone hydrochloride extended-release tablets are indicated in opioid-tolerant patients for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 7, 2016 | Original application | Approved |
| Hydromorphone Hydrochloride8MG · tablet, extended release;oral | Hydromorphone Hydrochloride | Rx |
| Hydromorphone Hydrochloride12MG · tablet, extended release;oral | Hydromorphone Hydrochloride | Rx |
| Hydromorphone Hydrochloride16MG · tablet, extended release;oral | Hydromorphone Hydrochloride | Rx |
| Hydromorphone Hydrochloride32MG · tablet, extended release;oral | Hydromorphone Hydrochloride | Rx |
| Hydromorphone Hydrochloride24MG · tablet, extended release;oral | Hydromorphone Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 23REMS | Approved | None posted |
| Dec 22, 2025 | Supplement 22Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 21REMS | Approved | None posted |
| Oct 30, 2024 | Supplement 20Manufacturing | Approved | None posted |
| Mar 12, 2024 | Supplement 19Labeling · Standard review | Approved | None posted |
| Dec 15, 2023 | Supplement 18Labeling · Standard review | Approved | None posted |
| Dec 15, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Mar 4, 2021 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 3, 2021 | Supplement 11Labeling · Standard review | Approved | None posted |
| Mar 3, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 6REMS | Approved | None posted |
| May 26, 2017 | Supplement 3REMS | Approved | None posted |
| Sep 30, 2016 | Supplement 1REMS | Approved | None posted |
| Jul 7, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters